Inhibition and induction of CYP enzymes in humans: an update
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
[HTML][HTML] EGFR first-and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
N Karachaliou, M Fernandez-Bruno… - Translational Cancer …, 2019 - ncbi.nlm.nih.gov
Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …
[HTML][HTML] Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant …
CY Yang, WY Liao, CC Ho, KY Chen, TH Tsai… - European journal of …, 2020 - Elsevier
Introduction Besides being a predictive biomarker of response to immunotherapy in lung
cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with …
cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with …
[HTML][HTML] Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - Springer
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …
[HTML][HTML] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
Objective We conducted a meta-analysis to synthesize the results of published randomized
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer
K Perdrizet, NB Leighl - Current treatment options in oncology, 2019 - Springer
Opinion statement The treatment of advanced non-small cell lung cancer (NSCLC) has
evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected …
evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected …
Antitumor effects of erlotinib in combination with berberine in A431 cells
X Cuan, X Yang, W Zhu, Y Zhao, R Luo… - BMC Pharmacology and …, 2023 - Springer
Background First-generation epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs), such as erlotinib, have been shown to target tumors with L858R (exon 21) and …
(EGFR-TKIs), such as erlotinib, have been shown to target tumors with L858R (exon 21) and …
Potential Benefits of Bevacizumab Combined with Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
I Tanaka, M Morise, A Miyazawa, Y Kodama… - Clinical Lung Cancer, 2020 - Elsevier
Background Oncogenic EGFR signaling has been shown to upregulate vascular endothelial
growth factor A (VEGFA) expression involved in tumor angiogenesis. However, the clinical …
growth factor A (VEGFA) expression involved in tumor angiogenesis. However, the clinical …